Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Pediatric Hematologic Malignancies: early-phase trial registry

1 of 1 indexed Pediatric Hematologic Malignancies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Pediatric Hematologic Malignancies: 1 US clinical trial tracked, 1 recruiting.

Pediatric Hematologic Malignancies is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 1 of these trials.

Enrollment posture brief

Registry condition pediatric-hematologic-malignancies

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Pediatric Hematologic Ma (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Pediatric Hematologic Malignancies

Pediatric Hematologic Malignancies lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pediatric Hematologic Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pediatric Hematologic Malignancies is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Pediatric Hematologic Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus Device
1 trials

US sites by state

Facility locations filed on Pediatric Hematologic Malignancies trials. A trial with sites in several states counts in each.

Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pediatric Hematologic Malignancies page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pediatric Hematologic Malignancies condition card totals 1 registered trials; most-linked intervention Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.